Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Back to dashboard
Company Information
About this company
Key people
Peter Rothschild
Chairman of the Board
Staffan Stroemberg
Chief Executive Officer
Maria Ekdahl
Chief Financial Officer
Anders Kronstroem
Chief Technical Officer
Margareta Hagman
Independent Director
Eva Iden
Independent Director
Anthon Jahreskog
Independent Director
Kristina Sjoeblom Nygren
Independent Director
Click to see more
Key facts
- Shares in issue13.02m
- EPICIBT B
- ISINSE0008015259
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 878.72m
- Employees8
- ExchangeStockholm Stock Exchange
- IndexSX All Share PI Market Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.